GM1 ganglioside reduces edema and monoaminergic neuronal changes following experimental focal ischemia in rat brain

Area of Science:

• Neuroscience
• Cerebrovascular Research
• Pharmacology

Background:

• Middle cerebral artery occlusion (MCAO) leads to ischemic brain injury, characterized by increased water content and neurotransmitter depletion.
• Understanding the neuroprotective potential of therapeutic agents is crucial for managing stroke outcomes.

Purpose of the Study:

• To investigate the effect of monosialoganglioside GM1 on brain water content and neurotransmitter levels following experimental ischemic stroke.
• To evaluate the neuroprotective efficacy of GM1 in a middle cerebral artery occlusion model.

Main Methods:

• An experimental model of middle cerebral artery occlusion was established in rodents.
• Animals received exogenous monosialoganglioside GM1 (30 mg/kg, i.p.) at specific intervals post-occlusion.
• Brain water content and levels of dopamine and serotonin were measured 72 hours after occlusion.

Main Results:

• GM1 administration significantly reduced the increase in water content on the ischemic side of the brain.
• Treatment with GM1 attenuated the loss of dopamine and serotonin on the ischemic side.
• Dopamine levels were approximately 50% and serotonin levels were 80% of contralateral levels in the ischemic hemisphere; GM1 treatment reduced this depletion.

Conclusions:

• Exogenous administration of monosialoganglioside GM1 demonstrates a protective effect against ischemic brain injury.
• GM1 mitigates both the edema formation and the depletion of key neurotransmitters like dopamine and serotonin following MCAO.
• These findings support the potential therapeutic role of GM1 in managing ischemic stroke.